Tempus AI Grew Revenue 83% But Is Still Burning $112 Million a Year in Cash

NEW YORK, April 10 —

Tempus AI has beaten earnings estimates for four straight quarters, improving EPS from -$0.24 to -$0.04 in less than a year. Wall Street responded with a consensus price target of $75.43, implying 71% upside from today's $44.16. There's just one problem: the company burned $112 million in cash over the trailing twelve months, and nothing about the latest Gilead collaboration suggests that number is about to shrink.

What the Street Believes

The consensus narrative on Tempus is clean and compelling. Revenue nearly doubled. Losses are narrowing fast. The company sits at the intersection of AI and healthcare, two sectors investors will pay almost anything for. Analysts have set a mean target of $75.43, and Cathie Wood's ARK Innovation ETF has been a prominent holder, lending the stock a growth-at-any-price halo. The thesis goes: Tempus is building a flywheel where genomic testing generates data, data attracts pharma partners, and pharma partnerships fund more testing. Give it time and the margins will come.

But here's the question nobody on the sell side is answering: if revenue grew 83% and gross margins are 62.7%, where did the cash go? A company with $1.3 billion in revenue and nearly two-thirds gross margin should be generating cash, or at least approaching breakeven. Instead, Tempus burned $112 million. That gap between reported earnings improvement and actual cash generation is the entire story, and the consensus is ignoring it.

What the Data Actually Shows

Follow the EPS trajectory and you'd think Tempus is sprinting toward profitability. Four quarters ago, the company lost $0.24 per share versus a $0.27 estimate. Three quarters ago, -$0.22 versus -$0.25. Two quarters ago, -$0.11 versus -$0.18, a 40% beat. The improvement looks real. It looks like operating leverage kicking in, like a company growing into its cost structure. But free cash flow tells a completely different story.

At -$112 million in trailing free cash flow, Tempus is burning cash at roughly the same rate it was when revenue was far smaller. That means the EPS improvement is substantially driven by non-cash items rather than actual dollars staying in the business. Stock-based compensation is the usual suspect in cases like this. It reduces GAAP losses (since it attracts talent without cash outflows) while doing nothing for the bank account. Think of it as a restaurant that reports lower food costs because the chef agreed to work for equity instead of salary. The P&L improves, but the kitchen still needs cash to buy ingredients.

"Tempus will provide real-world evidence analytics to support Gilead's oncology pipeline development."

The Gilead collaboration, announced this week, fits a pattern. Tempus has been signing pharma partnerships at an accelerating pace, and each one gets framed as a "strategic collaboration." But the critical question for investors is whether these deals represent recurring platform revenue, the kind that renews annually and compounds, or episodic data licensing, the kind where Tempus sells access to a dataset once and then needs to find the next buyer. The distinction matters enormously for valuation. A SaaS-like data platform deserves 10-15x revenue. A consulting shop that monetizes proprietary datasets one deal at a time deserves 3-5x. At $44.16, the market is pricing Tempus closer to the former.

Here's what the math actually says: $1.3 billion in revenue at 62.7% gross margin produces roughly $815 million in gross profit. To still be burning $112 million in free cash flow after generating $815 million in gross profit, operating expenses and capital needs must be consuming over $900 million a year. Revenue can double and you still won't see positive cash flow unless the cost structure fundamentally changes.

Why This Changes Everything

The consensus $75.43 target implies Tempus will be worth roughly $13 billion at that price. For that to make sense, you need to believe the company reaches meaningful positive free cash flow within the next two to three years. That requires not just continued revenue growth, but a dramatic shift in the relationship between revenue and cash. Right now, every additional dollar of revenue is costing Tempus more than a dollar to deliver. Growth is not yet self-funding.

Watch the FCF line, not the EPS line. If Tempus reports another quarter of narrowing GAAP losses while free cash flow stays flat or worsens, that confirms the earnings improvement is a non-cash phenomenon. On the other hand, if FCF loss narrows to -$50 million or better over the next two quarters while revenue keeps growing, the operating leverage thesis is real and the stock is cheap. Until then, the $75 target is pricing in a margin structure that has never existed at this company.

The revenue mix question is equally urgent. If Tempus breaks out its genomics testing revenue from pharma data licensing revenue in future filings, investors will finally be able to see which business is actually driving growth. If the majority of the 83% growth came from lumpy pharma deals rather than recurring diagnostic testing, the multiple contracts immediately. Pharma collaborations are project-based by nature. They end. And when they do, the comp gets harder, not easier.

The Bull Case

The bulls aren't wrong about everything. 83% revenue growth is extraordinary at any scale, and $1.3 billion is real scale. The genomics-to-data flywheel, if it works, creates a competitive moat that is genuinely hard to replicate. Tempus has more clinical data than almost anyone outside of major hospital systems, and that data appreciates in value as the AI models trained on it improve. If you believe the cash burn is a land-grab investment, spending money now to lock in data advantages that pay off for decades, then -$112 million is a bargain.

And the EPS trajectory, even if partially non-cash, does show the loss rate decelerating. A company going from -$0.24 to -$0.04 per share is doing something right operationally. The question is whether "something right" means "approaching sustainable profitability" or just "managing the optics of the income statement." For now, the FCF number says it's closer to the latter, but one strong cash flow quarter could change the narrative entirely.

The Bottom Line

Tempus AI is a $1.3 billion revenue company that cannot generate cash. The four-quarter EPS improvement from -$0.24 to -$0.04 is real on paper, but the -$112 million in free cash flow reveals that the path to profitability is far less advanced than the income statement suggests. Every new pharma "strategic collaboration," including the Gilead deal, should be evaluated not for its headline value but for whether it represents repeatable, platform-driven revenue or a one-time data sale. Until Tempus proves its unit economics work independent of episodic pharma deals, the $75 consensus target is a bet on a margin structure that doesn't exist yet. The stock is interesting below $30, where the growth alone might justify the price without requiring a profitability leap of faith. Run the free Tempus AI, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why is Tempus AI's free cash flow negative if revenue is growing so fast?

Despite $1.3 billion in trailing revenue and 62.7% gross margins, Tempus's operating expenses and capital needs consume more than the gross profit generated. The EPS improvement over recent quarters is driven substantially by non-cash items like stock-based compensation, which reduce reported losses but don't put cash in the bank.

What is the Tempus AI and Gilead real-world evidence collaboration?

Tempus announced it will provide real-world evidence analytics to support Gilead's oncology pipeline development. For investors, the key question is whether this deal generates recurring platform revenue that compounds over time, or represents a one-time data licensing event that won't repeat at the same scale.

How does Tempus AI make money from genomics and data?

Tempus has two broad revenue streams: genomic testing services for clinical use and data licensing or analytics partnerships with pharmaceutical companies. The revenue mix between these two matters enormously for valuation, since recurring diagnostic testing is worth a higher multiple than episodic pharma data deals.

Is Tempus AI stock overvalued at $44 per share?

With a -707x forward P/E ratio and -$112 million in free cash flow, the current price requires investors to believe Tempus will achieve a margin structure it has never demonstrated. The $75.43 consensus target implies 71% upside, but that valuation depends on the company proving it can convert revenue growth into actual cash generation within the next few years.

When will Tempus AI become profitable?

While GAAP losses have narrowed from -$0.24 to -$0.04 EPS over four quarters, free cash flow has not improved at the same rate. Genuine profitability, meaning positive free cash flow, likely requires either a fundamental shift in the cost structure or a revenue mix that tilts more toward high-margin recurring diagnostics rather than lower-durability pharma data deals.